December 3, 2019

Appili Therapeutics Enters Commercial Agreement With Saptalis Pharmaceuticals for Anticipated Launch of ATI-1501 Antibiotic Candidate in the U.S.

December 2, 2019

Appili Therapeutics Names Dr. Armand Balboni as Chief Executive Officer

November 27, 2019

Appili Therapeutics Reports Financial Results for Second Quarter of Fiscal Year 2020

November 21, 2019

Appili Therapeutics Acquires Clinical Stage Antifungal Program From FUJIFILM Toyama Chemical

November 18, 2019

Researchers Present New Positive Interim Data on Appili Therapeutics’ ATI-1701 Biodefense Program at 2019 Chemical and Biological Defense Science & Technology Conference

September 26, 2019

Appili Therapeutics Announces Voting Results of Annual and Special Meeting of Shareholders

September 16, 2019

Appili Therapeutics Retains BND Projects for Strategic Investor Relations Services

August 21, 2019

Appili Therapeutics Reports Financial Results for First Quarter of Fiscal Year 2020

August 20, 2019

Researchers to Present New Data on Appili Therapeutics Infectious Disease Programs at the 2019 Military Health System Research Symposium

July 3, 2019

Appili Therapeutics Announces FY 2019 Financial Results

July 2, 2019

Appili Therapeutics Signs $3M USD Grant Contract with the United States Department of Defense to Develop Antibiotics that Target Superbugs

June 24, 2019

Appili Therapeutics Common Shares to Begin Trading on June 25, 2019 on the TSXV Under the Stock Symbol “APLI”

June 13, 2019

Appili Therapeutics Announces Filing of Final Prospectus 

April 10, 2019

Appili Therapeutics Receives Government of Canada Assistance to Support Continued Growth of its Novel Anti-Infective Pipeline

April 8, 2019

Appili Therapeutics to Present at 2019 Bloom Burton & Co. Healthcare Investor Conference

March 25, 2019

Appili Therapeutics Announces Closing of $3.6 Million Special Warrant Private Placement and Filing of Preliminary Prospectus